Adipose Tissue and Serum Inflammation in GH Deficiency
Adipose Tissue and Serum Inflammation in Growth Hormone (GH) Deficiency
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carlos Reyes-Vidal, MD
- Phone Number: 212-305-4921
- Email: csr52@columbia.edu
Study Contact Backup
- Name: Pamela Freda, MD
- Phone Number: 212-305-2254
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- Males or females age ≥18 years with diagnosis of GH deficiency that is Adult Onset, either alone or associated with multiple pituitary hormone deficiencies and due to pituitary disease,hypothalamic disease, surgery, radiation therapy or Childhood Onset due to congenital, genetic, acquired, or idiopathic causes.
- Diagnosis of GH deficiency defined by: insulin tolerance test or glucagon test: peak growth hormone response < 3 ng/ml or 3 or more pituitary hormone deficiencies and IGF-1 standard deviation score < -2.0
- No history of diabetes mellitus and fasting blood sugar at screening visit ≤ 120 mg/dl.
- If patients have undergone surgical resection of a pituitary adenoma, a minimum of 12 months must have elapsed post surgery prior to enrollment and tumor will be demonstrated to be unchanged for 12 months or longer since surgery.
- May have a history of radiotherapy, but they must have completed their course of radiotherapy more than 3 months prior to study screening.
- If prior GH therapy must have not received prior growth hormone replacement therapy in 310 the 6 months prior to screening.
- Stable pituitary hormone supplements (x 3 months) prior to baseline visit and normal levels of free thyroxine, testosterone in males and normal adrenal function if not on replacement therapy.
- If female, a. Not pregnant (as evidenced by a negative serum pregnancy test) or lactating and b. If of childbearing potential, agrees to use a medically acceptable form of contraception (such as oral, implantable, or barrier contraception) from the time of screening, for the duration of the study, and for at least one month after study discontinuation or completion. Childbearing potential is defined as women who are not surgically sterile or not at least one year postmenopausal.
- Sign and date an informed consent document indicating that the subject (or legally acceptable representative) has been informed of and agrees to all pertinent aspects of the trial.
Exclusion Criteria:
- Have other conditions that may result in abnormal GH and/or IGF-I concentrations (e.g., severe hepatic disease, severe renal disease, malnutrition, treatment with levodopa).
- Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≥ 2 x upper limit of normal or clinically significant hepatic disease or renal impairment defined as creatinine > 1.5x upper normal.
- Have a pituitary adenoma with a distance to the optic chiasm of 5 mm or less, confirmed by a recent MRI scan (within two months prior to the screening visit).
- Pituitary tumor growth within the 12 months prior to study entry.
- GH therapy within 6 months of screening.
- Diabetes mellitus.
- History of acromegaly.
- History of active Cushing's disease within 24 months of screening
- Visual field defects or other neurological symptoms due to current tumor mass compression.
- Have known or suspected drug or alcohol abuse.
- Have received an investigational medication within four weeks prior to Screening or is scheduled to receive any investigational medication during the study.
- Do not have the ability to fully comprehend the nature of the study, to follow instructions, cooperate with study procedures, and/or are unable to adhere to the visit scheduled outlined in the protocol.
- Have other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- History of a malignancy other than squamous or basal cell skin carcinoma that has been excised or intracranial malignant tumors or leukemia within 5 years of screening.
- Patients who have a known hypersensitivity to growth hormone therapy
- Use of weight 349 loss medications
- Females who plan to change estrogen therapy during the trial
- Patients who have received supraphysiologic doses of glucocorticoids within the past 6 months (except for peri-operative (< 3 days duration) of dexamethasone), or who are currently receiving any chemotherapeutic agents.
- Patients who have received other investigational drugs administered or received within 30 days of study entry
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Adults with growth hormone deficiency
Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
|
Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
Other Names:
|
|
Control group
Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visceral Adipose Tissue (VAT) mass
Time Frame: Baseline to 12 months of GH therapy
|
Visceral adipose tissue mass as measured by tota body magnetic resonance imaging
|
Baseline to 12 months of GH therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra-hepatic lipid level
Time Frame: Baseline to 12 months of GH therapy
|
Intra-hepatic lipid level measured by magnetic resonance imaging of liver
|
Baseline to 12 months of GH therapy
|
|
Skeletal Muscle Mass
Time Frame: Baseline to 12 months of GH therapy
|
Skeletal muscle mass measured by total body magnetic resonance imaging
|
Baseline to 12 months of GH therapy
|
|
Total body fat
Time Frame: Baseline to 12 months of GH therapy
|
Total body fat as measured by dual x-ray absorptiometry
|
Baseline to 12 months of GH therapy
|
|
Resting metabolic rate
Time Frame: Baseline to 12 months of GH therapy
|
Resting metabolic rate
|
Baseline to 12 months of GH therapy
|
|
Relative gene expression of CD68 gene
Time Frame: Baseline to 12 months of GH therapy
|
Relative gene expression values of Cluster of Differentiation 68 (CD68) gene expression in adipose tissue
|
Baseline to 12 months of GH therapy
|
|
Relative gene expression values of MCP1 gene
Time Frame: Baseline to 12 months of GH therapy
|
Relative gene expression values of monocyte chemoattractant protein-1 (MCP-1) gene in adipose tissue
|
Baseline to 12 months of GH therapy
|
|
Relative gene expression IL6 gene
Time Frame: Baseline to after 12 months of treatment for GH deficiency
|
Relative gene expression Interleukin 6 (IL6) gene in adipose tissue
|
Baseline to after 12 months of treatment for GH deficiency
|
|
Relative gene expression values of CD11c gene
Time Frame: Baseline to 12 months of GH therapy
|
Relative gene expression values of CD11c gene in adipose tissue
|
Baseline to 12 months of GH therapy
|
|
interleukin 6 (IL-6) level
Time Frame: Baseline to 12 months of GH therapy
|
Plasma level of interleukin 6 (IL-6)
|
Baseline to 12 months of GH therapy
|
|
TNFα level
Time Frame: Baseline to 12 months of GH therapy
|
Plasma level of tumor necrosis factor alpha (TNFα)
|
Baseline to 12 months of GH therapy
|
|
CRP level
Time Frame: Baseline to 12 months of GH therapy
|
Plasma level of C-reactive protein (CRP)
|
Baseline to 12 months of GH therapy
|
|
homocysteine level
Time Frame: Baseline to 12 months of GH therapy
|
Plasma level of homocysteine
|
Baseline to 12 months of GH therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Pamela U. Freda, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAAP3950
- 1R01DK110771-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.